WO2015037659A1 - 水溶液製剤及びその製造方法 - Google Patents
水溶液製剤及びその製造方法 Download PDFInfo
- Publication number
- WO2015037659A1 WO2015037659A1 PCT/JP2014/074065 JP2014074065W WO2015037659A1 WO 2015037659 A1 WO2015037659 A1 WO 2015037659A1 JP 2014074065 W JP2014074065 W JP 2014074065W WO 2015037659 A1 WO2015037659 A1 WO 2015037659A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- aqueous solution
- compound represented
- compound
- diseases
- producing
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/04—Drugs for disorders of the respiratory system for throat disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
Definitions
- the present invention relates to an aqueous solution preparation containing N- [3,5-bis (trifluoromethyl) phenyl] -5-chloro-2-hydroxybenzamide as an active ingredient and a method for producing the same.
- Formula (I) It is known that the compound represented by the formula (hereinafter referred to as Compound (I)) is useful for preventing or ameliorating various diseases and useful as various preparations (Patent Documents 1 to 40). And non-patent documents 1 to 35).
- An object of the present invention is to provide an aqueous solution preparation containing compound (I) and a method for producing the same.
- the present inventors have dissolved the compound (I) and the compound represented by the following general formula (II), (III) or (IV) in an organic solvent. Thereafter, by removing the organic solvent from this solution, it was found that the obtained residue could be dissolved in water or an aqueous solution, that is, an aqueous solution preparation containing Compound (I) could be produced, and the present invention was completed.
- a compound represented by the following formula (I) or a pharmacologically acceptable salt thereof and a compound represented by any one of the following general formulas (II) to (IV) are dissolved in an organic solvent.
- a first step of preparing a dissolving solution; a second step of removing the organic solvent from the dissolving solution; and a third step of dissolving the residue by adding a solution to the residue obtained by the second step A method for producing an aqueous solution preparation comprising a step; [2] The method for producing an aqueous solution preparation according to the above [1], wherein n of the compound represented by the general formula (II) is 14 or 37; [3] The method for producing an aqueous solution preparation according to the above [1], wherein n of the compound represented by the general formula (III) is 46; [4] The method for producing an aqueous solution preparation according to the above [1], wherein n of the compound represented by the general formula (IV) is 46; [5] An
- an aqueous solution preparation containing Compound (I) and a method for producing the same can be provided.
- the aqueous solution preparation of the present invention i.e., the aqueous solution preparation containing compound (I) as an active ingredient, compound (I) or a pharmacologically acceptable salt, and general formulas (II) and (III) Or a first step of preparing a solution in which the compound represented by (IV) is dissolved, a second step of removing the organic solvent from the solution, and a solution in the residue obtained by the second step. And a third step of dissolving the residue.
- Compound (I) can be produced, for example, based on the method described in US Patent Application Publication No. 2004/0259877. Moreover, the pharmacologically acceptable salt of compound (I) can be produced by a method widely used in the art. Examples of the pharmacologically acceptable salt of compound (I) include metal salts such as lithium salt, sodium salt, potassium salt, magnesium salt and calcium salt, or ammonium salt, methylammonium salt, dimethylammonium salt and trimethyl. Mention may be made of ammonium salts such as ammonium salts and dicyclohexylammonium salts.
- the compound represented by the general formula (II) has an average molecular weight of 1000 to 2000, that is, n (average number of units of polyethylene glycol (PEG) contained in the compound) is an integer of 14 to 37. Although it will not be restrict
- the compound represented by the general formula (III) is not particularly limited as long as the average molecular weight of polyethylene glycol is 1000 to 2000, that is, n is an integer of 22 to 46. It is preferable to use one having an average molecular weight of polyethylene glycol of 2000, that is, n of 46.
- the compound represented by the general formula (III) can be produced according to the method described in US Pat. No. 6,679,822.
- the compound represented by the general formula (IV) is not particularly limited as long as the average molecular weight of polyethylene glycol is 1000 to 2000, that is, n is an integer of 22 to 46. It is preferable to use one having an average molecular weight of polyethylene glycol of 2000, that is, n of 46.
- the organic solvent is not particularly limited as long as it can dissolve the compound (I) or a pharmacologically acceptable salt and the compound represented by the general formula (II), (III) or (IV).
- primary alcohols such as methanol, ethanol, isopropanol, tert-butanol, dimethyl sulfoxide (DMSO), methyl tert-butyl ether, N, N-dimethylacetamide, N, N-dimethylformamide, acetone, N -Methyl-2-pyrrolidone, tetrahydrofuran, acetonitrile or ethyl acetate, or a mixture thereof can be used, and a pharmaceutically acceptable organic solvent such as ethanol, N-methyl-2-pyrrolidone, dimethyl sulfoxide can be used. preferable.
- the temperature at which compound (I) or a pharmacologically acceptable salt, and a compound represented by general formula (II), (III) or (IV) is dissolved in an organic solvent may be compound (I) or a drug.
- the salt is not particularly limited as long as it is a temperature at which a physically acceptable salt and the compound represented by the general formula (II), (III) or (IV) can be dissolved in an organic solvent.
- the melting temperature is, for example, a temperature range of 50 to 60 ° C.
- the solution added to the residue obtained by removing the organic solvent from the solution is not particularly limited as long as it is a pharmaceutically acceptable solution.
- a pharmaceutically acceptable solution for example, water for injection (water), physiological saline A glucose aqueous solution, Ringer's solution, lactated Ringer's solution, or the like can be used.
- the temperature at which this solution is added to the residue to dissolve the residue is not particularly limited as long as the temperature can dissolve the residue in the solution.
- the melting temperature of the residue is, for example, a temperature range of 0 to 60 ° C., preferably a temperature range of 4 to 55 ° C., and more preferably a temperature range of room temperature (23 to 25 ° C.) to 55 ° C.
- the aqueous solution preparation obtained by the method for producing an aqueous solution preparation of the present invention has any concentration range that can be used as a preparation such as an injection, that is, any concentration as long as 1 mg or more of Compound (I) is dissolved in 1 mL of the solution. However, a high concentration is preferable in that the dose can be reduced.
- the aqueous solution preparation of the present invention produced as described above can be used for the prevention (including suppression of progression / deterioration) or improvement of the diseases described in Patent Documents 1 to 40 or Non-Patent Documents 1 to 35, for example. Useful for treatment, prolongation of life, etc.).
- Diseases include, for example, autoimmune diseases, inflammatory diseases, allergic diseases, tumors, cancers, carcinomas, sarcomas, blood diseases, cardiovascular diseases, respiratory diseases, digestive diseases, liver diseases, lung diseases, urological diseases, Endocrine diseases, metabolic diseases, eye diseases, otolaryngology diseases, skin diseases, neurological diseases, brain diseases, connective tissue diseases, musculoskeletal diseases, viral diseases, bacterial diseases, thrombosis and the like can be mentioned.
- the above diseases include rheumatoid arthritis, osteoarthritis, systemic lupus erythematosus, systemic scleroderma, polymyositis, Sjogren's syndrome, vasculitis syndrome, antiphospholipid antibody syndrome, Still's disease, Behcet's disease , Periarteritis nodosa, ulcerative colitis, Crohn's disease, active chronic hepatitis, glomerulonephritis, chronic nephritis, chronic pancreatitis, gout, atherosclerosis, multiple sclerosis, intimal thickening, psoriasis, psoriatic Arthritis, contact dermatitis, atopic dermatitis, eczema, hay fever, hives, vasculitis, rhinitis, gastroenteropathy, diarrhea, neuritis, otitis media, granulomatosis, cystitis, laryngitis, purpur
- the injectable composition of the present invention can also be used as an organ deterioration preventive agent when pre-transplant organ preservation.
- prevention and / or improvement of tumor or its synonyms include tumoricidal action or anticancer action, tissue or cell canceration inhibiting action, tumor metastasis inhibiting action, existing antitumor agent Intensive action of drugs, action to overcome drug resistance to existing antitumor agents, cancer epidemic improvement action, prevention of recurrence, life-prolonging action of tumor patients, etc.
- prevention or improvement of Alzheimer's disease includes amyloid ⁇ protein accumulation inhibitory effect, nerve cell death inhibitory effect, brain atrophy inhibitory effect, neurofibrillary tangle change inhibitory effect, dementia improving effect, and the like.
- epilepsy includes epileptic seizure suppression (eg, tonic-clonic seizure, absence seizure, myoclonic seizure, etc.), cerebral nerve cell abnormal excitation suppression, hippocampal neuronal cell death suppression, etc. including.
- the aqueous solution preparation of the present invention may further contain one or two or more additives that are acceptable as components of the aqueous solution preparation, in addition to the residue and the solution.
- the additive include a buffer such as sodium phosphate; a stabilizer such as sodium pyrosulfite; an osmotic pressure regulator such as sodium chloride, mannitol and glycerin; a soothing agent such as lidocaine; and a preservative such as phenol.
- a buffer such as sodium phosphate
- a stabilizer such as sodium pyrosulfite
- an osmotic pressure regulator such as sodium chloride, mannitol and glycerin
- a soothing agent such as lidocaine
- a preservative such as phenol.
- the necessary amount of the injectable composition of the present invention may be administered to the administration subject at one time, intermittently, or continuously.
- Examples of the continuous administration method include infusion administration.
- the injectable composition of the present invention can be suitably used for the improvement of acute diseases requiring urgent administration of a therapeutic agent.
- diseases include cerebrovascular disorders such as stroke, ischemic heart disease such as acute myocardial infarction, and the like.
- the injectable composition of the present invention can be suitably used for the improvement of diseases that require continuous administration of a therapeutic agent.
- SUNBRIGHT registered trademark
- CS-010 and CS-020 are used as examples of the compound represented by the general formula (II), and the compound represented by the general formula (III) is used.
- SUNBRIGHT registered trademark
- DSPE-020CN NOF Co., Ltd.
- SUNBRIGHT registered trademark
- DSPE-020GL2U NOF Corporation
- Example 1 to Example 7 Preparation of aqueous solution containing compound (I) Drug [Compound (I)], the compound shown in the table below and ethanol were added to a vial and heated to 55-60 ° C. And the compound was completely dissolved in ethanol (colorless and transparent without causing precipitation and precipitation) to prepare each dissolution solution.
- Each lysis solution was warmed at 60 ° C. for 1.5 hours, and the contents were evaporated to dryness.
- a predetermined amount of physiological saline or water was added to the resulting residue, and the mixture was heated to 55 ° C. (incubated at room temperature for 24 hours in Example 6. Incubated at 4 ° C. for 72 hours in Example 7) for dissolution. It was.
- the storage stability is excellent without being clouded or producing precipitates or precipitates at 4 ° C. or at room temperature for at least 2 months.
- I was able to confirm.
- the aqueous solution of Example 3 was excellent in storage stability without becoming cloudy or producing precipitates or precipitates at 4 ° C. for at least 2 months.
- the aqueous solution of Example 7 was excellent in storage stability without becoming cloudy or producing precipitates or precipitates at 4 ° C. for at least one month.
- Example 1 Pharmacokinetic test using the aqueous solution obtained in Example 1 The aqueous solution obtained in Example 1 was filtered and sterilized with Millex (registered trademark) -GV (0.22 ⁇ m; Nippon Millipore Corporation / Merck Millipore). Then, it was intravenously administered to male and female Sprague-Daweley IGS rats (6 weeks old), and the kinetics of compound (I) was examined.
- Millex registered trademark
- ⁇ Test method> As the animal group, male and female Sprague-Daweley IGS rats (Charles River Japan) were used. The rats were 6 weeks old and weighed 166-189 g for males and 123-145 g for females. The rats were quarantined and acclimatized for 7 days in a SPF (Specific pathogen free) animal laboratory, and at the same time the health condition was observed. Rats were housed one in each gauge in a sterilized stainless steel gauge. In the SPF animal laboratory, the room temperature was maintained at 20.6-22.5 ° C. and the relative humidity was maintained at 44-60%. Ventilation in the SPF animal laboratory was performed 15 times per hour. The lighting in the SPF animal laboratory was switched between bright and dark every 12 hours.
- SPF Standard pathogen free
- the animal sample used was a rod-shaped dry basic sample (component analysis completed).
- the drinking water was tap water that was confirmed to be within the reference value by analysis, and rats were allowed to ingest freely.
- the quarantined rats were randomly divided into the following 3 groups (4 males and 4 females per group) according to body weight.
- Group 3 Group to administer 3 mL / kg of the aqueous solution obtained in Example 1 After the quarantined rats were fasted overnight (about 16 hours), the aqueous solution obtained in Example 1 was intravenously administered.
- Blood was collected 0.083 hours, 0.25 hours, 0.5 hours, 1 hour, 4 hours, and 24 hours after administration, and the blood concentration of compound (I) was measured. From the measured blood concentration of compound (I) at each sampling time, the maximum blood concentration C 0 (ng / mL) immediately after intravenous administration of the injectable composition, and the compound (I ) AUC 0-24 (ng ⁇ h / mL) under the blood concentration curve was calculated.
- Example 1 From the results of the present confirmation example, it is clear that the aqueous solution obtained in Example 1 can be exposed in a dose-dependent and sufficient amount, as an active ingredient, by intravenous administration into the living body. It became. Further, in this confirmed example, there were no deaths in the rats, and no toxicological findings that could cause serious disability were observed.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Physical Education & Sports Medicine (AREA)
- Diabetes (AREA)
- Biomedical Technology (AREA)
- Pulmonology (AREA)
- Neurosurgery (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Pain & Pain Management (AREA)
- Oncology (AREA)
- Cardiology (AREA)
- Ophthalmology & Optometry (AREA)
- Urology & Nephrology (AREA)
- Dermatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Communicable Diseases (AREA)
- Obesity (AREA)
- Molecular Biology (AREA)
- Virology (AREA)
- Biophysics (AREA)
- Endocrinology (AREA)
Abstract
Description
本発明は、化合物(I)を含有する水溶液製剤及びその製造方法を提供することを目的とする。
[1] 有機溶媒に下式(I)で表される化合物又は薬理学的に許容されるその塩、及び下記の一般式(II)~(IV)のいずれかで表される化合物を溶解した溶解液を調製する第1の工程と、前記溶解液から前記有機溶媒を取り除く第2の工程と、第2の工程によって得られた残留物に溶液を加えて前記残留物を溶解する第3の工程を含むことを特徴とする水溶液製剤の製造方法;
[3] 一般式(III)で表される化合物のnが46である上記[1]に記載の水溶液製剤の製造方法;
[4] 一般式(IV)で表される化合物のnが46である上記[1]に記載の水溶液製剤の製造方法;
[5] 上記[1]~[4]のいずれかに記載の水溶液製剤の製造方法により得られる水溶液製剤などである。
なお、本発明の目的、特徴、利点、及びそのアイデアは、本明細書の記載により、当業者には明らかであり、当業者であれば本明細書の記載から容易に本発明を再現できる。以下に記載された発明の実施の形態及び具体的な実施例などは、本発明の好ましい実施態様を示すものであり、例示又は説明のために示されているものであって、本発明をそれらに限定するものではない。本明細書で開示されている本発明の意図並びに範囲内で、本明細書の記載に基づき、様々な改変並びに修飾ができることは、当業者にとって明らかである。
バイアルに、薬剤[化合物(I)]と下表に示される化合物とエタノールを加えて55~60℃に加温し、薬剤及び化合物をエタノールに完全に(析出物及び沈殿物が生じることなく、無色透明に)溶解させ、各溶解溶液を調製した。各溶解溶液を60℃で1.5時間加温し、内容物を蒸発乾固させた。得られた残渣に生理食塩水又は水を所定量加えて55℃に加温し(実施例6では室温にて24時間インキュベーションした。実施例7では4℃で72時間インキュベーションした。)、溶解させた。バイアル内の水溶液をそれぞれ目視したところ、水溶液は析出物及び沈殿物がなく、無色澄明であったことから、薬剤が完全に溶解し、少なくとも1mg/mlの濃度で化合物(I)を含有する水溶液をそれぞれ調製できることが確認できた。なお、下表に示される化合物以外の化合物を用いて、1mg/mlの濃度で化合物(I)を含有する水溶液を調製することを試みたが、下表に示される化合物以外では、薬剤が完全に溶解した水溶液を調製できなかった。
実施例1で得られた水溶液をMillex(登録商標)-GV(0.22μm; 日本ミリポア株式会社/メルクミリポア)で濾過、滅菌し、雌雄Sprague-Daweley系IGSラット(6週齢)に静脈内投与し、化合物(I)の動態を調べた。
動物群は、雌雄Sprague-Daweley系IGSラット(チャールズリバージャパン)を用いた。前記ラットは6週齢であり、体重は、雄が166~189g、雌が123~145gであった。
前記ラットをSPF(Specific pathogen free)動物実験室で7日間検疫、馴化し、同時に健康状態を観察した。ラットは、滅菌済ステンレス製ゲージ内で、各ゲージに1匹ずつ飼育した。SPF動物実験室内は、室内温度を20.6~22.5℃に、相対湿度を44~60%に維持した。SPF動物実験室内の換気は、1時間あたり15回実施した。SPF動物実験室内の照明は、12時間ごとに明るい状態と暗い状態に切り替えた。
前記の検疫済ラットを体重によってランダムに、下記の3群(1群あたり雌雄各4匹)に群分けした。
(1) グループ1:実施例1で得られた水溶液を1mL/kg投与する群
(2) グループ2:実施例1で得られた水溶液を2mL/kg投与する群
(3) グループ3:実施例1で得られた水溶液を3mL/kg投与する群
前記検疫済ラットを一夜(約16時間)空腹にした後、実施例1で得られた水溶液を静脈内投与し、投与から0.083時間、0.25時間、0.5時間、1時間、4時間、及び24時間後に血液を採取し、化合物(I)の血中濃度を測定した。測定した各採取時間における化合物(I)の血中濃度から、注射用組成物を静脈内投与した直後の最大血中濃度C0(ng/mL)、及び投与後0~24時間における化合物(I)の血中濃度曲線下面積AUC0-24(ng・h/mL)を算出した。
Claims (5)
- 一般式(II)で表される化合物のnが14又は37である請求項1に記載の水溶液製剤の製造方法。
- 一般式(III)で表される化合物のnが46である請求項1に記載の水溶液製剤の製造方法。
- 一般式(IV)で表される化合物のnが46である請求項1に記載の水溶液製剤の製造方法。
- 請求項1~4のいずれかに記載の水溶液製剤の製造方法により得られる水溶液製剤。
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US14/917,638 US9974860B2 (en) | 2013-09-13 | 2014-09-11 | Aqueous solution formulation and method for manufacturing same |
EP14844160.3A EP3045169B1 (en) | 2013-09-13 | 2014-09-11 | Aqueous solution formulation, and manufacturing method for same |
JP2015536623A JP6083770B2 (ja) | 2013-09-13 | 2014-09-11 | 水溶液製剤及びその製造方法 |
CN201480050141.2A CN105636583B (zh) | 2013-09-13 | 2014-09-11 | 水溶液制剂及其制造方法 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2013191192 | 2013-09-13 | ||
JP2013-191192 | 2013-09-13 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2015037659A1 true WO2015037659A1 (ja) | 2015-03-19 |
Family
ID=52665759
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2014/074065 WO2015037659A1 (ja) | 2013-09-13 | 2014-09-11 | 水溶液製剤及びその製造方法 |
Country Status (5)
Country | Link |
---|---|
US (1) | US9974860B2 (ja) |
EP (1) | EP3045169B1 (ja) |
JP (1) | JP6083770B2 (ja) |
CN (1) | CN105636583B (ja) |
WO (1) | WO2015037659A1 (ja) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9827253B2 (en) | 2013-11-06 | 2017-11-28 | Aeromics, Inc. | Prodrug salts |
US9994514B2 (en) | 2012-05-08 | 2018-06-12 | Aeromics, Inc. | Methods of treating cerebral edema and spinal cord edema |
Citations (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3331874A (en) | 1962-05-29 | 1967-07-18 | Herbert C Stecker | Bistrifluoromethyl anilides |
US3332996A (en) | 1961-03-25 | 1967-07-25 | Cassella Farbwerke Mainkur Ag | Trifluoromethyl-substituted salicylanilides |
US6679822B2 (en) | 2001-03-02 | 2004-01-20 | Nof Corporation | Polyalkylene oxide-modified phospholipid and production method thereof |
US20040259877A1 (en) | 2000-12-18 | 2004-12-23 | Susumu Muto | Inhibitors against the production and release of inflammatory cytokines |
US20060014811A1 (en) | 2002-06-10 | 2006-01-19 | Susumu Muto | Medicament for treatment of cancer |
US20060019958A1 (en) | 2002-06-05 | 2006-01-26 | Susumu Muto | Immunity-related protein kinase inhibitors |
WO2006013873A1 (ja) | 2004-08-05 | 2006-02-09 | Institute Of Medicinal Molecular Design. Inc. | シクロオキシゲナーゼ阻害作用を有する医薬 |
US20060035944A1 (en) | 2002-06-11 | 2006-02-16 | Susumu Muto | Remedies for neurodegenerative diseases |
US20060089395A1 (en) | 2002-06-10 | 2006-04-27 | Susumu Muto | Nf-kb activation inhibitors |
US20060094718A1 (en) | 2002-06-06 | 2006-05-04 | Susumu Muto | O-substituted hydroxyaryl derivatives |
US20060100257A1 (en) | 2002-06-05 | 2006-05-11 | Susumu Muto | Inhibitors against the activation of ap-1 and nfat |
US20060111409A1 (en) | 2002-06-05 | 2006-05-25 | Susumu Muto | Medicament for treatment of diabetes |
US20060122243A1 (en) | 2002-06-06 | 2006-06-08 | Susumu Muto | Antiallergic |
JP2006160696A (ja) * | 2004-12-09 | 2006-06-22 | Nof Corp | 難水溶性薬剤用可溶化剤組成物 |
US20070042997A1 (en) | 2003-07-16 | 2007-02-22 | Akiko Itai | Medicament for treatment of dermal pigmentation |
US20070254956A1 (en) | 2003-10-29 | 2007-11-01 | Koichi Shudo | Medicament for Therapeutic and/or Preventive Treatment of Restenosis or Reocclusion After Vascular Recanalization Operation |
WO2008041066A1 (en) | 2006-10-02 | 2008-04-10 | Clipper Windpower Technology, Inc. | Wind turbine with blade pitch control to compensate for wind shear and wind misalignment |
WO2008094410A2 (en) | 2007-02-01 | 2008-08-07 | Albert Einstein College Of Medicine Of Yeshiva University | Parallel profiling of signaling pathways |
WO2008133884A2 (en) | 2007-04-23 | 2008-11-06 | Combinatorx, Incorporated | Methods and compositions for the treatment of neurodegenerative disorders |
WO2009006555A2 (en) | 2007-07-02 | 2009-01-08 | Yu, Ming | Methods, composition, targets for combinational cancer treatments |
WO2009074809A1 (en) | 2007-12-13 | 2009-06-18 | University Of Dundee | Sigma ligands and ikk / nf - kb inhibitors for medical treatment |
WO2009082514A1 (en) | 2007-12-21 | 2009-07-02 | University Of Rochester | Molecular targets for treatment of inflammation |
US20090239868A1 (en) | 2007-10-23 | 2009-09-24 | Institute Of Medical Molecular Design, Inc. | Inhibitor of pai-1 production |
WO2010000903A2 (es) | 2008-06-30 | 2010-01-07 | Centro De Investigaciones Energéticas, Medioambientales Y Tecnológicas (Ciemat) | Composición capaz de modular la actividad de ikkalpha para el tratamiento de enfermedades que cursan con acantolisis |
WO2010048273A2 (en) | 2008-10-21 | 2010-04-29 | President And Fellows Of Harvard College | Methods and compounds for treatment of neurodegenerative disorders |
WO2010096574A1 (en) | 2009-02-20 | 2010-08-26 | Lisanti Michael P | A method of diagnosis or prognosis of a neoplasm comprising determining the level of expression of a protein in stromal cells adjacent to the neoplasm |
WO2010099731A1 (en) | 2009-03-01 | 2010-09-10 | Ming Yu | Compounds, compositions and use for anticancer therapy |
WO2010106082A1 (en) | 2009-03-16 | 2010-09-23 | Genmedica Therapeutics Sl | Anti-inflammatory and antioxidant conjugates useful for treating metabolic disorders |
JP2011140470A (ja) * | 2010-01-08 | 2011-07-21 | Toray Ind Inc | 親水性生理活性物質含有微粒子の製造方法 |
WO2011133879A2 (en) | 2010-04-22 | 2011-10-27 | University Of Massachusetts | Combination therapies with mitochondrial-targeted anti-tumor agents |
WO2012019284A1 (en) | 2010-08-11 | 2012-02-16 | Universite De Montreal | Combinatory cancer treatment |
WO2012024612A1 (en) | 2010-08-20 | 2012-02-23 | Pangea Biosciences, Inc. | Cancer diagnostic and cancer therapeutic |
JP2012102107A (ja) * | 2004-06-30 | 2012-05-31 | Centre National De La Recherche Scientifique | ゲムシタビン誘導体ナノ粒子 |
WO2012148799A1 (en) * | 2011-04-28 | 2012-11-01 | Board Of Regents, The University Of Texas System | Improved parenteral formulations of lipophilic pharmaceutical agents and methods for preparing and using the same |
JP2013199476A (ja) * | 2012-02-23 | 2013-10-03 | Canon Inc | 粒子、及び、それを有する光イメージング用造影剤 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102133172B (zh) * | 2011-01-24 | 2012-11-14 | 北京大学 | 一种紫杉醇纳米胶束及其应用 |
CN102293736B (zh) * | 2011-08-31 | 2013-06-05 | 兰州大学 | 紫杉醇-聚合物载药胶束制备工艺 |
-
2014
- 2014-09-11 WO PCT/JP2014/074065 patent/WO2015037659A1/ja active Application Filing
- 2014-09-11 EP EP14844160.3A patent/EP3045169B1/en active Active
- 2014-09-11 US US14/917,638 patent/US9974860B2/en active Active
- 2014-09-11 CN CN201480050141.2A patent/CN105636583B/zh active Active
- 2014-09-11 JP JP2015536623A patent/JP6083770B2/ja active Active
Patent Citations (44)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3332996A (en) | 1961-03-25 | 1967-07-25 | Cassella Farbwerke Mainkur Ag | Trifluoromethyl-substituted salicylanilides |
US3331874A (en) | 1962-05-29 | 1967-07-18 | Herbert C Stecker | Bistrifluoromethyl anilides |
US20040259877A1 (en) | 2000-12-18 | 2004-12-23 | Susumu Muto | Inhibitors against the production and release of inflammatory cytokines |
US20100274051A1 (en) | 2000-12-18 | 2010-10-28 | Institute Of Medicinal Molecular Design. Inc. | Inflammatory cytokine release inhibitor |
US20080318956A1 (en) | 2000-12-18 | 2008-12-25 | Institute Of Medicinal Molecular Design. Inc. | Inflammatory cytokine release inhibitor |
US20080249071A1 (en) | 2000-12-18 | 2008-10-09 | Institute Of Medicinal Molecular Design. Inc. | Inflammatory cytokine release inhibitor |
US6679822B2 (en) | 2001-03-02 | 2004-01-20 | Nof Corporation | Polyalkylene oxide-modified phospholipid and production method thereof |
US20060111409A1 (en) | 2002-06-05 | 2006-05-25 | Susumu Muto | Medicament for treatment of diabetes |
US20060100257A1 (en) | 2002-06-05 | 2006-05-11 | Susumu Muto | Inhibitors against the activation of ap-1 and nfat |
US20060019958A1 (en) | 2002-06-05 | 2006-01-26 | Susumu Muto | Immunity-related protein kinase inhibitors |
US20070185059A1 (en) | 2002-06-06 | 2007-08-09 | Institute Of Medicinal Molecular Design, Inc. | Antiallergic agents |
US20060122243A1 (en) | 2002-06-06 | 2006-06-08 | Susumu Muto | Antiallergic |
US20060094718A1 (en) | 2002-06-06 | 2006-05-04 | Susumu Muto | O-substituted hydroxyaryl derivatives |
US20070185110A1 (en) | 2002-06-06 | 2007-08-09 | Institute Of Medicinal Molecular Design, Inc. | Antiallergic agents |
US20100113770A1 (en) | 2002-06-06 | 2010-05-06 | Institute Of Medicinal Molecular Design, Inc. | O-substituted hydroxyaryl derivatives |
US20080090779A1 (en) | 2002-06-06 | 2008-04-17 | Institute Of Medicinal Molecular Design, Inc. | Antiallergic agents |
US20060089395A1 (en) | 2002-06-10 | 2006-04-27 | Susumu Muto | Nf-kb activation inhibitors |
US20080311074A1 (en) | 2002-06-10 | 2008-12-18 | Institute Of Medical Molecular Design Inc. | Inhibitors against activation of NF-kappaB |
US20060014811A1 (en) | 2002-06-10 | 2006-01-19 | Susumu Muto | Medicament for treatment of cancer |
US20080234233A1 (en) | 2002-06-11 | 2008-09-25 | Institute Of Medicinal Molecular Design Inc. | Medicament for treatment of neurodegenerative diseases |
US20060035944A1 (en) | 2002-06-11 | 2006-02-16 | Susumu Muto | Remedies for neurodegenerative diseases |
US20070042997A1 (en) | 2003-07-16 | 2007-02-22 | Akiko Itai | Medicament for treatment of dermal pigmentation |
US20070254956A1 (en) | 2003-10-29 | 2007-11-01 | Koichi Shudo | Medicament for Therapeutic and/or Preventive Treatment of Restenosis or Reocclusion After Vascular Recanalization Operation |
JP2012102107A (ja) * | 2004-06-30 | 2012-05-31 | Centre National De La Recherche Scientifique | ゲムシタビン誘導体ナノ粒子 |
WO2006013873A1 (ja) | 2004-08-05 | 2006-02-09 | Institute Of Medicinal Molecular Design. Inc. | シクロオキシゲナーゼ阻害作用を有する医薬 |
JP2006160696A (ja) * | 2004-12-09 | 2006-06-22 | Nof Corp | 難水溶性薬剤用可溶化剤組成物 |
WO2008041066A1 (en) | 2006-10-02 | 2008-04-10 | Clipper Windpower Technology, Inc. | Wind turbine with blade pitch control to compensate for wind shear and wind misalignment |
WO2008094410A2 (en) | 2007-02-01 | 2008-08-07 | Albert Einstein College Of Medicine Of Yeshiva University | Parallel profiling of signaling pathways |
WO2008133884A2 (en) | 2007-04-23 | 2008-11-06 | Combinatorx, Incorporated | Methods and compositions for the treatment of neurodegenerative disorders |
WO2009006555A2 (en) | 2007-07-02 | 2009-01-08 | Yu, Ming | Methods, composition, targets for combinational cancer treatments |
US20090239868A1 (en) | 2007-10-23 | 2009-09-24 | Institute Of Medical Molecular Design, Inc. | Inhibitor of pai-1 production |
WO2009074809A1 (en) | 2007-12-13 | 2009-06-18 | University Of Dundee | Sigma ligands and ikk / nf - kb inhibitors for medical treatment |
WO2009082514A1 (en) | 2007-12-21 | 2009-07-02 | University Of Rochester | Molecular targets for treatment of inflammation |
WO2010000903A2 (es) | 2008-06-30 | 2010-01-07 | Centro De Investigaciones Energéticas, Medioambientales Y Tecnológicas (Ciemat) | Composición capaz de modular la actividad de ikkalpha para el tratamiento de enfermedades que cursan con acantolisis |
WO2010048273A2 (en) | 2008-10-21 | 2010-04-29 | President And Fellows Of Harvard College | Methods and compounds for treatment of neurodegenerative disorders |
WO2010096574A1 (en) | 2009-02-20 | 2010-08-26 | Lisanti Michael P | A method of diagnosis or prognosis of a neoplasm comprising determining the level of expression of a protein in stromal cells adjacent to the neoplasm |
WO2010099731A1 (en) | 2009-03-01 | 2010-09-10 | Ming Yu | Compounds, compositions and use for anticancer therapy |
WO2010106082A1 (en) | 2009-03-16 | 2010-09-23 | Genmedica Therapeutics Sl | Anti-inflammatory and antioxidant conjugates useful for treating metabolic disorders |
JP2011140470A (ja) * | 2010-01-08 | 2011-07-21 | Toray Ind Inc | 親水性生理活性物質含有微粒子の製造方法 |
WO2011133879A2 (en) | 2010-04-22 | 2011-10-27 | University Of Massachusetts | Combination therapies with mitochondrial-targeted anti-tumor agents |
WO2012019284A1 (en) | 2010-08-11 | 2012-02-16 | Universite De Montreal | Combinatory cancer treatment |
WO2012024612A1 (en) | 2010-08-20 | 2012-02-23 | Pangea Biosciences, Inc. | Cancer diagnostic and cancer therapeutic |
WO2012148799A1 (en) * | 2011-04-28 | 2012-11-01 | Board Of Regents, The University Of Texas System | Improved parenteral formulations of lipophilic pharmaceutical agents and methods for preparing and using the same |
JP2013199476A (ja) * | 2012-02-23 | 2013-10-03 | Canon Inc | 粒子、及び、それを有する光イメージング用造影剤 |
Non-Patent Citations (36)
Title |
---|
AM. J. PHYSIOL. HEART CIRC. PHYSIOL., vol. 292, no. 1, 2007, pages H530 - 538 |
AM. J. PHYSIOL. LUNG CELL MOL. PHYSIOL., vol. 298, no. 2, 2010, pages L197 - 209 |
AM. J. RESPIR. CRIT. CARE MED., vol. 173, no. 9, 2006, pages 1016 - 1022 |
BASIC CLIN. PHARMACOL. TOXICOL., vol. 101, no. 6, 2007, pages 401 - 406 |
BIOCHEM. BIOPHYS. RES. COMMUN., vol. 323, no. 1, 2004, pages 242 - 248 |
BLOOD, vol. 105, no. 6, 2005, pages 2324 - 2331 |
CADIOVASC. RES., vol. 63, no. 1, 2004, pages 8 - 10 |
CANCER RES., vol. 66, no. 1, 2006, pages 419 - 426 |
CANCER RES., vol. 67, no. 7, 2007, pages 3220 - 3228 |
CANCER SCI., vol. 103, no. 1, 2012, pages 100 - 106 |
CARDIOVASC. RES., vol. 63, no. 1, 2004, pages 51 - 59 |
CLIN. EXP. ALLERGY, vol. 41, no. 1, 2011, pages 104 - 115 |
CLIN. EXP. NEPHROL., vol. 15, no. 1, 2011, pages 41 - 49 |
CURR. CANCER DRUG TARGETS, vol. 7, no. 5, 2007, pages 492 - 503 |
CYTOKINE, vol. 54, no. 2, 2011, pages 161 - 166 |
DRUG METAB. DISPOS., vol. 40, no. 1, 2012, pages 205 - 211 |
EUR. J. PHARMACOL., vol. 637, no. 1-3, 2010, pages 148 - 154 |
EXPERT. OPIN. INVESTIG. DRUGS, vol. 20, no. 3, 2011, pages 395 - 405 |
GLYCOBIOLOGY, vol. 19, no. 7, 2009, pages 776 - 788 |
HISTOCHEM. CELL BIOL., vol. 133, no. 3, 2010, pages 339 - 348 |
INFECT. IMMUN., vol. 76, no. 2, 2008, pages 781 - 787 |
INT. ARCH. ALLERGY IMMUNOL., vol. 148, no. 3, 2009, pages 186 - 198 |
J. GASTROENTEROL., vol. 44, no. 9, 2009, pages 935 - 943 |
J. INVEST. DERMATOL., vol. 127, no. 4, 2007, pages 855 - 863 |
J. MED. DENT. SCI., vol. 55, no. 1, 2008, pages 49 - 59 |
J. NEUROINFLAMMATION, vol. 8, 2011, pages 107 |
J. VIRAL HEPAT., vol. 18, no. 10, 2011, pages E439 - 446 |
MOD. RHEUMATOL., vol. 17, no. 6, 2007, pages 459 - 463 |
RADIAT. RES., vol. 171, no. 1, 2009, pages 9 - 21 |
RES. VET. SCI., vol. 89, no. 3, 2010, pages 378 - 382 |
SCIENTIFIC WORLD JOURNAL, vol. 10, 2010, pages 2139 - 2156 |
SPINE (PHILA PA 1976, vol. 33, no. 23, 2008, pages 2489 - 2494 |
TANAKA A. ET AL.: "A novel NF-KB inhibitor, IMD- 0354, suppresses neoplastic proliferation of human mast cells with constitutively activated c-kit receptors.", BLOOD, vol. 105, no. 6, 2005, pages 2324 - 2331, XP055326674 * |
TOXICOL. APPL. PHARMACOL., vol. 249, no. 1, 2010, pages 25 - 32 |
TOXICOL. LETT., vol. 209, no. 2, 2012, pages 107 - 112 |
WORLD J. GASTROENTEROL., vol. 17, no. 47, 2011, pages 5203 - 5213 |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9994514B2 (en) | 2012-05-08 | 2018-06-12 | Aeromics, Inc. | Methods of treating cerebral edema and spinal cord edema |
US11084778B2 (en) | 2012-05-08 | 2021-08-10 | Aeromics, Inc. | Methods of treating cardiac edema, neuromyelitis optica, and hyponatremia |
US11873266B2 (en) | 2012-05-08 | 2024-01-16 | Aeromics, Inc. | Methods of treating or controlling cytotoxic cerebral edema consequent to an ischemic stroke |
US9827253B2 (en) | 2013-11-06 | 2017-11-28 | Aeromics, Inc. | Prodrug salts |
US9949991B2 (en) | 2013-11-06 | 2018-04-24 | Aeromics, Inc. | Methods of treating aquaporin-mediated conditions |
US10258636B2 (en) | 2013-11-06 | 2019-04-16 | Aeromics, Inc. | Prodrug salts |
US10894055B2 (en) | 2013-11-06 | 2021-01-19 | Aeromics, Inc. | Pharmaceutical compositions, methods of making pharmaceutical compositions, and kits comprising 2-{[3,5-bis(trifluoromethyl)phenyl]carbamoyl}4-chlorophenyl dihydrogen phosphate |
US11071744B2 (en) | 2013-11-06 | 2021-07-27 | Aeromics, Inc. | Prodrug salts |
US11801254B2 (en) | 2013-11-06 | 2023-10-31 | Aeromics, Inc. | Pharmaceutical compositions and methods of making pharmaceutical compositions comprising 2-{[3,5-bis(trifluoromethyl)phenyl]carbamoyl}-4-chlorophenyl dihydrogen phosphate |
Also Published As
Publication number | Publication date |
---|---|
CN105636583A (zh) | 2016-06-01 |
EP3045169A4 (en) | 2017-04-26 |
CN105636583B (zh) | 2019-08-20 |
US20160220680A1 (en) | 2016-08-04 |
JP6083770B2 (ja) | 2017-02-22 |
EP3045169B1 (en) | 2018-05-02 |
EP3045169A1 (en) | 2016-07-20 |
JPWO2015037659A1 (ja) | 2017-03-02 |
US9974860B2 (en) | 2018-05-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5480804B2 (ja) | リポ酸誘導体を含有する医薬製剤 | |
WO2018003857A1 (ja) | 非経口投与用医薬組成物 | |
JP6083770B2 (ja) | 水溶液製剤及びその製造方法 | |
WO2008087461B1 (en) | Use of kynurenic acid and derivatives thereof in the treatment of conditions of the gastrointestinal tract accompanied by hypermotility and inflammation or gout or multiple sclerosis | |
US8202898B1 (en) | Pharmaceutical composition | |
JP2017519020A (ja) | コハク酸脱水素酵素阻害剤(SDHi’s) | |
Assis et al. | Synthesis, hypolipidemic, and anti-inflammatory activities of arylphthalimides | |
JP2007269769A (ja) | 神経変性疾患関連蛋白質凝集線維化抑制剤 | |
JP2021105061A (ja) | アミロイド線維形成の抑制又は阻害剤 | |
JP7430879B2 (ja) | アルブミン結合性を有するnoラジカル放出型抗がん剤としてのニトロ化フェニルカルボン酸誘導体 | |
FR3108502A1 (fr) | Dérivés de nicotinamide mononucléotides dans le traitement et la prévention des infections bactériennes | |
US20130084330A1 (en) | Composition for the treatment of arthritis containing a dibenzo-p-dioxin derivative as the active ingredient | |
EP3237015B1 (fr) | Derives hydroxybisphosphoniques hydrosolubles de la doxorubicine | |
RU2663848C1 (ru) | 5-Фтор-2-(4-этоксикарбонилпиперазин-1-ил)-1,3-бензотиазин-4-он, обладающий противотуберкулезной активностью | |
US11730712B2 (en) | Functionalized long-chain hydrocarbon mono- and di-carboxylic acids and derivatives thereof, and their use for the prevention or treatment of disease | |
US11111219B2 (en) | Polysubstituted pyrimidines inhibiting the formation of prostaglandin E2, a method of production thereof and use thereof | |
WO2024133757A1 (en) | Cyclodextrin derivatives for the treatment of gout and hyperuricemia | |
JP2021165241A (ja) | 細胞内コレステロール輸送障害治療薬及び予防薬 | |
RAY et al. | COMPOUNDS FOR CANCER RESEARCH. II. 1 FLUORENE-2-CARBOXAMIDINE | |
WO2022251382A1 (en) | Modulating expression level of a gene encoding an uncoupling protein by treating a human subject with a nitroxide | |
JPH0532550A (ja) | 血小板凝集阻害剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 14844160 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 14917638 Country of ref document: US |
|
ENP | Entry into the national phase |
Ref document number: 2015536623 Country of ref document: JP Kind code of ref document: A |
|
REEP | Request for entry into the european phase |
Ref document number: 2014844160 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2014844160 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |